BioSpace News Archive

Henry Ford Innovations (HFI) has signed an exclusive licensing agreement with a Detroit software and health care company to market an innovative software application that will be appealing to specialty pharmacies worldwide.

Researchers at Boston Medical Center (BMC) and Boston University School of Medicine (BUSM), in collaboration with Columbia University Irving Medical Center (CUIMC), are leading a national, multi-site study aimed to achieve earlier diagnosis of transthyretin cardiac amyloidosis (ATTR-CM).

Beyond Next Ventures Inc. and DENSO Corporation today announced that they have established OPExPARK Inc., a carve-out*1 to develop the businesses utilizing OPeLiNK®*2. OPExPARK will develop and sell systems that integrate information from surgery equipment, produce educational content for physicians, and offer distribution services.

The Foundation for Sarcoidosis Research (FSR) is teaming up with internationally-recognized physicians to host an educational conference for people affected by sarcoidosis in Boston.

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units (“RSUs”) to 15 new employees in connection with their employment with UroGen.

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it has re-priced its non-brokered private placement originally announced on August 1, 2019 (the “Offering”).

The Honourable Mary Ng, Minister of Small Business and Export Promotion, participated in a panel discussion on implementing medical innovation at the 2019 edition of the Toronto Global Forum hosted by the International Economic Forum of the Americas.

Health Canada is advising Canadians who use vaping products to monitor themselves for symptoms of pulmonary illness (e.g., cough, shortness of breath, chest pain) and to seek medical attention promptly if they have concerns about their health.

Audentes Therapeutics, Inc. announced it has granted equity awards that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to seventeen individuals hired by Audentes from July 16 through August 31, 2019.

The U.S. Food and Drug Administration today issued the following Consumer Update: